Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2021 / N 2

Опыт применения дупилумаба в лечении тяжелой бронхиальной астмы
И.В. Демко, Е.А. Собко, Н.А. Шестакова, А.Ю. Крапошина, Н.В. Гордеева

References

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2021. Available from: https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf Accessed 2021 Dec 06.
2. Ministry of Health of the Russian Federation; Russian Respiratory Society; Russian Association of Allergologists and Clinical Immunologists; Union of Pediatricians of Russia. Bronchial asthma. Clinical recommendations. International statistical classification of diseases and related health problems (ICD): J45, J46. Year of approval (frequency of revision): 2021. Age category: adults, children. Year of expiration: 2023. Moscow, 2021. 114 p. Available from: https://spulmo.ru/upload/rekomendacyi_bronh_astma_21_23.pdf Accessed 2021 Dec 06. (In Russian).
3. Fedoseyev GB, Trofimov VI, Shaporova NL, Aleksandrin VA, Filippova NA, Kryakunov KN. Searching for truth: what is bronchial asthma? Pulmonologiya 2015;25(1):5-18 (In Russian).
4. Wenzel SE. Severe asthma: from characteristics to phenotypes to endotypes. Clinical & Experimental Allergy 2012 May;42(5):650-8.
5. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. American Journal of Respiratory and Critical Care Medicine 2009 Sep;180(5):388-95.
6. Bhakta NR, Woodruff PG. Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunological Reviews 2011 Jul;242(1):220-32.
7. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Medicine 2012 May;18(5):716-25.
8. Sergeyeva GR, Yemelyanov AV, Korovina OV, Znakhurenko AA, Leshenkova EV, Kozyreva LV, Asatiani N. Severe asthma: characteristics of patients in clinical practice. Therapeutic Archive 2015;87(12):26-31 (In Russian).
9. Denlinger LC, Phillips BR, Ramrathan S, Ross K, Bhakta NR, Cardet JC, Castro M, Peters SP, Phipatanakul W, Aujla S, Bacharier LB, Bleecker ER, Comhair SAA, Coverstone A, DeBoer M, Erzurum SC, Fain SB, Fajt M, Fitzpatrick AM, Gaffin J, Gaston B, Hastie AT, Hawkins GA, Holguin F, Irani AM, Israel E, Levy BD, Ly N, Meyer DAS, Moore WC, Myers R, Opina MTD, Peters MC, Schiebler ML, Sorkness RL, Teague WG, Wenzel SE, Woodruff PG, Mauger DT, Fahy JV, Jarjour NN; National Heart, Lung, and Blood Institute’s Severe Asthma Research Program-3 Investigators. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. American Journal of Respiratory and Critical Care Medicine 2017 Feb;195(3):302-13.
10. Nenasheva NM. T2-high and T2-low bronchial asthma: endotype characteristics and biomarkers. Pulmonologiya 2019;29(2):216-28 (In Russian).
11. Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respiratory Research 2019 Aug;20(1):179.
12. Nenasheva NM. Omalizumab in therapy of severe bronchial asthma. Effective Pharmacotherapy 2014;29:24-35 (In Russian).
13. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. The New England Journal of Medicine 2009 Mar;360(10):973-84.
14. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. American Journal of Respiratory and Critical Care Medicine 2011;184(10):1125-32.
15. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G. Dupilumab in persistent asthma with elevated eosinophil levels. The New England Journal of Medicine 2013 Jun;368(26):2455-66.
16. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. The Lancet. Respiratory Medicine 2014 Nov;2(11):879-90.
17. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. The New England Journal of Medicine 2018 Jun;378(26):2486-96.
18. Diamont Z, Dahlén SE. Type 2 inflammation and the evolving profile of uncontrolled persistent asthma. EMJ 2018 Dec;3(4):24-33.
19. Blauvelt A, Simpson EL, Tyring SK, Purcell LA, Shumel B, Petro CD, Akinlade B, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Evans R. Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. Journal of the American Academy of Dermatology 2019 Jan;80(1):158-67.e1.
20. Webb DC, McKenzie AN, Koskinen AM, Yang M, Mattes J, Foster PS. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. Journal of Immunology (Baltimore, Md.: 1950) 2000 Jul;165(1):108-13.
21. Zayed Y, Kheiri B, Banifadel M, Hicks M, Aburahma A, Hamid K, Bachuwa G, Chandran A. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. The Journal of Asthma 2019 Oct;56(10):1110-9.
22. Dyneva ME, Aminova GE, Kurbacheva OM, Ilyina NI. Dupilumab: new opportunities for the treatment of asthma and chronic rhinosinusitis with nasal polyps. Russian Journal of Allergy 2021;18(1):18-31 (In Russian).
23. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. The New England Journal of Medicine 2018 Jun;378(26):2475-85.
24. Tozawa H, Kanki Y, Suehiro J, Tsutsumi S, Kohro T, Wada Y, Aburatani H, Aird WC, Kodama T, Minami T. Genome-wide approaches reveal functional interleukin-4-inducible STAT6 binding to the vascular cell adhesion molecule 1 promoter. Molecular and Cellular Biology 2011 Jun;31(11):2196-209.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]